

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Caligiuri et al.	
Serial No.:	10/589,840	Art Unit: 1628
Filed:	May 17, 2007	Examiner: A. Pagonakis
Entitled:	METHODS FOR TREATING RESISTANT OR REFRACTORY TUMORS	

Attorney Docket No.: GPC-298.1P US

**Mail Stop Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT UNDER 37 CFR §§ 1.56, 1.97, AND 1.98**

Dear Sir:

In accordance with the duty of disclosure under 37 CFR § 1.56, Applicants submit this Information Disclosure Statement pursuant to 37 CFR §§ 1.97 and 1.98 in the above-identified application for consideration by the Patent Office.

This information disclosure statement is filed pursuant to 37 CFR §§ 1.97(c)(2). The Commissioner is authorized to charge the fee of \$180.00 under 37 CFR § 1.17(p) to Deposit Account No. 50-0268. The Commissioner is authorized to charge any additional fees required in connection with the filing of this paper, or to credit any overpayment, to Deposit Account No. 50-0268. A listing of the cited documents (modified USPTO Form 1449) is also enclosed.

**Non-Patent Literature Documents**

Calabresi et al., *Section IX Chemotherapy of Neoplastic Diseases - Introduction*, Goodman & Gilman's *The Pharmacological Basis of Therapeutics* 10th ed., (J. Hardman, L. Limbird, and A. Gilman eds.), (McGraw-Hill, New York, 2001) (pp. 1381, 1383-1385 and 1388 provided);

Engblom et al., "Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines", *British Journal of Cancer*, 79(2): 286-292 (1999);

Engblom et al., "Carboplatin-Paclitaxel-and Carboplatin-Docetaxel-Induced Cytotoxic Effect in Epithelial Ovarian Carcinoma in Vitro", *Cancer*, 86: 2066-2073 (1999);

**NPL Documents (Continued)**

Fokkema et al., "JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin", *Biochemical Pharmacology*, 63: 1989-1996 (2002);

Gura, T., "Systems for Identifying New Drugs Are Often Faulty", *Science*, 278(5340): 1041-1042 (1997);

Kelland, L.R., "An update on satraplatin: the first orally available platinum anticancer drug", *Exp. Opin. Invest. Drugs*, 9(6): 1373-1382 (2000);

Moreno et al., "Phase II study of docetaxel and cisplatin in first line treatment of disseminated small cell lung cancer (SCLC): Preliminary results", *European Journal of Cancer*, 35: S262 (1999);

Petrylak, D.P., "Docetaxel for the Treatment of Hormone-Refractory Prostate Cancer", *Reviews in Urology*, 5(Suppl. 2): S14-S21 (2003);

Van Putten et al., "Docetaxel and carboplatin combination as second-line treatment in metastatic non-small-cell lung cancer (NSCLC)", *European Journal of Cancer*, 37: S51 (2001); and

Vogelstein et al., Chapter 1, In The Genetic Basis of Human Cancer 2nd ed., (B. Vogelstein and K. Kinzler eds.), (McGraw-Hill, 2002) p. 3.

Applicants do not intend to represent that any of the documents submitted herein is material prior art to this invention or that the list represents an exhaustive search of documents related to this invention.

Applicants respectfully request that the documents submitted herein be considered and made of record in this application, and also printed on any patent issuing from the above-identified application.

Respectfully submitted,



---

David G. O'Brien, Reg. No. 46,125  
Leon R. Yankwich, Reg. No. 30,237  
Attorneys for Applicants  
YANKWICH & ASSOCIATES, P.C.  
201 Broadway  
Cambridge, Massachusetts 02139  
telephone: (617) 374-3700  
telefax: (617) 374-0055

**Certificate of Transmission via EFS-Web**

The undersigned hereby certifies that this correspondence and accompanying documents are being electronically submitted to the U.S. Patent Office on April 23, 2010.

**/David G. O'Brien/**